Editas Medicine (EDIT) Free Cash Flow (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Free Cash Flow of -$30.8 million for Q3 2025, up 44.44% year-over-year from -$21.4 million in Q3 2024, and up 38.58% quarter-over-quarter from -$50.2 million in Q2 2025.
Editas Medicine (EDIT) Free Cash Flow (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Free Cash Flow for 11 consecutive years, with -$30.8 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Free Cash Flow rose 44.44% year-over-year to -$30.8 million; the TTM figure through Dec 2025 stood at -$127.8 million (up 41.66% YoY), while the FY2024 annual figure was -$219.1 million, down 60.05% from the prior year.
- Free Cash Flow grew to -$30.8 million in Q3 2025 per EDIT's latest filing, from -$50.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$23.5 million in Q4 2023 and bottomed at -$60.6 million in Q2 2024.
- Historically, Free Cash Flow has averaged -$44.1 million across 5 years, with a median of -$43.1 million in 2021.
- Annual changes were most pronounced in 2023 — Free Cash Flow jumped 45.11% — and 2024, when it tumbled 117.87%.
- Editas Medicine's Free Cash Flow stood at -$37.4 million in 2021, then retreated by 14.62% to -$42.9 million in 2022, then surged by 45.11% to -$23.5 million in 2023, then sank by 117.87% to -$51.3 million in 2024, then soared by 39.88% to -$30.8 million in 2025.
- Business Quant data shows EDIT's Free Cash Flow at -$30.8 million in Q3 2025, -$50.2 million in Q2 2025, and -$46.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -30.84 Mn |
| Sep 30, 2025 | -30.84 Mn |
| Jun 30, 2025 | -50.21 Mn |
| Jun 30, 2025 | -50.21 Mn |
| Mar 31, 2025 | -46.77 Mn |
| Mar 31, 2025 | -46.77 Mn |
| Dec 31, 2024 | -51.30 Mn |
| Dec 31, 2024 | -51.30 Mn |
| Sep 30, 2024 | -55.51 Mn |
| Sep 30, 2024 | -55.51 Mn |
| Jun 30, 2024 | -60.56 Mn |
| Jun 30, 2024 | -60.56 Mn |
| Mar 31, 2024 | -51.74 Mn |
| Mar 31, 2024 | -51.74 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -35.70 Mn |
| Sep 30, 2023 | -35.70 Mn |
| Jun 30, 2023 | -40.04 Mn |
| Jun 30, 2023 | -40.04 Mn |